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With the change in patient population toward older and sickerpatients undergoing cardiac surgery, neurologic injury hasemerged as perhaps the most important perioperative com-plication, and its frequency increases exponentially withincreasing age.1 Particular attention has been paid to therole of cardiopulmonary bypass per se2 and thromboem-
bolization from the ascending aorta.3 However, neurologic injury is not limited to
only stroke and coma1; increasingly there is a focus on the more subtle neurocog-
nitive dysfunction and its consequences on quality of life.4,5
The majority of cases of gross neurologic injury do not represent a diagnostic
problem, as at the time of diagnosis the injury is usually manifest and irreversible.
Neurocognitive dysfunction, however, is less accessible for quantification, which
requires time-consuming neuropsychologic testing. With only a few exceptions,
such testing has been unavailable for the cardiac surgeon. Prompted by the increas-
ing awareness of neurologic injury, as well as the emergence of minimally invasive
cardiac surgery, there is at present an increasing interest in cognitive testing.
However, such testing will remain a research method and not available in everyday
clinical practice because of the time and manpower it consumes.
A biochemical marker in the blood of the patients—“a troponin of the brain”—
would represent a revolution in the investigation and diagnosis of neurologic injury
in cardiac surgery. A serum marker could potentially identify which aspect(s) of
cardiac surgery are responsible for cognitive dysfunction and evaluate the efficacy
of alternative surgical techniques. Additionally, if marker concentrations during or
directly after surgery could be related to cognitive dysfunction or shown to predict
gross neurologic injury that became clinically evident after some hours (or days),
then potentially neuroprotective interventions might be indicated. 
The ideal biochemical marker should have the following properties:
1. Central nervous specificity 
2. Rapid and significant release into blood after injury, preferably within minutes
3. Elimination within a few hours
4. Rapidly and readily obtainable assay results 
5. Predictability of serious injury from an early sample, eg, at the end of surgery 
6. Relationship of marker concentration to the degree of injury, quantifying the 
full range from subtle cognitive deficits to gross injury 
7. Inexpensive
During the past two decades a variety of substances have been suggested as pos-
sible biochemical markers of brain injury, such as adenylate kinase, creatinine phos-
phokinase isoenzyme BB, lactate, myelin basic protein, S100β, and neuron-specific
enolase.6 Recently, glial fibrillary acidic protein has been added to this list,7 but its
potential role is unknown. Most of these substances have methodologic problems:
for instance, adenylate kinase and lactate have to be sampled directly from cere-
brospinal fluid, and creatinine phosphokinase isoenzyme BB lacks brain specificity.
The value of neuron-specific enolase was also recently shown to be doubtful
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because of its association with hemolysis caused by destruc-
tion of erythrocytes.8
S100β appeared to fulfill many of the above criteria of an
ideal marker.6,9,10 Serum S100β increases not only after car-
diac surgery, but also in Alzheimer disease, Down syndrome,
minor and major head injury, acute stroke, and after cardiac
arrest.9 It has been suggested to be a prognostic predictor for
the long-term consequences of minor head injuries and the
degree of anoxic brain injury after cardiac arrest.9
Cardiac surgery causes an increase of serum S100β after
less than an hour (ie, before cannulation), a further increase to
maximum blood levels at the end of cardiopulmonary bypass,
and thereafter it rapidly declines,6,9 although occasionally
with a late rise. Serum S100β has been correlated with age,
duration of cardiopulmonary bypass, duration of aortic cross-
clamping, duration of deep hypothermic circulatory arrest,
number of cerebral emboli during surgery, preoperative cere-
brovascular complications, and preoperative renal impair-
ment.9 The use of a filter in the arterial line or heparin-coated
surfaces reduces postoperative S100β levels.9 There are anec-
dotal reports that patients with operative cerebral injuries have
higher concentrations of S100β at the end of surgery.11,12 The
relation of S100β to neurocognitive dysfunction is controver-
sial, but most studies do not find such a correlation. 
These findings initiated the tremendous interest in S100β,
which was rapidly adopted as the marker of cerebral injury
until recent findings suggested the presence of a significant
noncerebral contribution. Patients operated on off-pump
were shown to lack the large increased concentration seen
after bypass, but an assay with increased sensitivity revealed
a puzzling increase after only the prebypass surgical
trauma.13 Jönsson and associates14 sampled blood every
hour for the first 10 hours postoperatively, detected brief ele-
vations of S100β that coincided with the time points of auto-
transfusion, and found a 20-fold increase of S100β in the
mediastinal shed blood compared with the regular blood
samples. Anderson and colleagues15,16 showed that if the
cardiotomy suction was replaced by a cell-saving device dur-
ing surgery with cardiopulmonary bypass, the serum S100β
concentrations during the whole perioperative period were
indistinguishable from those of patients operated on off-
pump. S100β in the cell-saving reservoir blood was 10-fold
greater than the maximum serum S100β in patients undergo-
ing conventional coronary artery bypass surgery with car-
diopulmonary bypass using a cardiotomy suction. Pleural
drainage blood from patients having a thoracotomy (no car-
diopulmonary bypass) contained equally large S100β con-
centrations as blood from mediastinal drains after on-pump
cardiac surgery.16 Very high levels of S100β were detected in
blood from the surgical wounds, from bone marrow aspirate,
in mediastinal fat, and in skeletal muscle—concentrations
that were up to 1000 times higher than the preoperative
blood concentrations.16 Brain specificity was not improved
by separate analysis of the two dimer subgroups that com-
prise S100β as it is commercially assayed.16 Both dimers
appear in serum after surgery and both arise from extracere-
bral sources, especially traumatized fat and muscle tissue.
Hopes to use serum S100β to screen patients who have
had head trauma are clouded by the finding that even trauma
patients without head injury have increased concentrations
of serum S100β, particularly after bone fractures, but even
after limited soft tissue trauma and burns. These noncerebral
contributions limit the usefulness of serum S100β in neuro-
surgery.17 Serum S100β increases seen after accidental or
only surgical trauma (such as after off-pump surgery or
on-pump surgery without a cardiotomy reservoir) may be
completely explained, although a cerebral contribution can-
not be excluded, by capillary and lymphatic uptake into the
circulation of the small (11-kd) S100 monomer due to the
high concentration difference between mediastinal blood
and the bloodstream.16
Consequently, extracerebral sources of S100β make the
interpretation of the early S100β blood concentrations dif-
ficult, and no valid conclusions concerning neurologic
injury in cardiac surgery can be drawn from the early
release. To a large extent, the correlations previously
detected for S100β levels after cardiopulmonary bypass
can be related to the use of the cardiotomy suction: a longer
operation or more complicated patient population means
that more blood is suctioned from the mediastinum with
increased return of mediastinal blood to the circulation, and
thus the higher serum S100β concentration. All previous
data on S100β should be reevaluated in light of this knowl-
edge. The similarity of release between on-pump (when a
cell saving system is used) and off-pump surgery suggests
that cardiopulmonary bypass per se does not release
S100β.15,16 These data imply that the early sampling of
S100β is useless in detecting neurologic damage after con-
ventional cardiac surgery using cardiopulmonary bypass
because of the high background noise of S100β release
from extracerebral sources. Late increases in serum S100β,
after 24 to 48 hours, have been related to perioperative
cerebral complications like stroke, delayed awakening, and
confusion.9,12 Unfortunately, this is neither helpful nor
really interesting, because at this stage the brain injury is
already manifest and irreversible and may be quantified in
other, probably more precise ways. The potentially most
interesting use of the serum S100β concentration would
have been a detectable contribution from the brain at or
immediately after the operation.
Two possibilities for the use of early S100β release exist:
1. Can an early high level of serum S100β predict that a
neurologic injury has occurred? This is probably only
possible if the cardiotomy reservoir has not been used.
The contributions from surgical trauma are smaller, but
as cardiopulmonary bypass makes no distinguishable
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addition, any correlation with cognitive dysfunction is
below the level of detection.
2. Sampling of cerebrospinal fluid for measurements of
S100β may avoid the above problems, although a spinal
tap may create additional problems. Spinal fluid
drainage presents a unique opportunity to compare cere-
brospinal fluid and blood levels of S100β. 
In this issue of the Journal, Kunihara, Shiiya, and
Yasuda18 compared values in serum and in cerebrospinal
fluid of patients undergoing surgery for thoracoabdominal
aneurysms. The number of patients in each group is small,
but the study shows higher sensitivity and earlier release of
S100β into the cerebrospinal fluid when spinal injury
occurred. More such studies are needed to investigate
whether S100β has any place at all as an early marker of
neurologic injury in cardiovascular surgery. At the present
time, using serum S100β concentrations immediately after
the end of bypass as a marker of neurologic injury is not
acceptable if a cardiotomy suction has been used. In addi-
tion, any tissue damage will limit its usefulness, particularly
in diagnosing the subtle changes of greatest interest.
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